Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$13.69 - $18.01 $20,535 - $27,015
-1,500 Reduced 3.31%
43,800 $669,000
Q2 2024

Aug 15, 2024

SELL
$14.59 - $18.48 $528,158 - $668,976
-36,200 Reduced 44.42%
45,300 $689,000
Q1 2024

May 07, 2024

BUY
$14.83 - $20.18 $154,232 - $209,872
10,400 Added 14.63%
81,500 $1.54 Million
Q4 2023

Feb 14, 2024

SELL
$13.43 - $19.63 $355,895 - $520,195
-26,500 Reduced 27.15%
71,100 $1.36 Million
Q3 2023

Nov 14, 2023

SELL
$17.62 - $23.54 $525,076 - $701,492
-29,800 Reduced 23.39%
97,600 $1.75 Million
Q2 2023

Aug 11, 2023

SELL
$16.97 - $22.03 $957,107 - $1.24 Million
-56,400 Reduced 30.69%
127,400 $2.59 Million
Q1 2023

May 16, 2023

BUY
$15.96 - $23.15 $857,052 - $1.24 Million
53,700 Added 41.28%
183,800 $3.35 Million
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $882,560 - $1.6 Million
44,800 Added 52.52%
130,100 $2.69 Million
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $1.45 Million - $1.87 Million
-62,300 Reduced 42.21%
85,300 $2.23 Million
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $792,580 - $1.74 Million
46,000 Added 45.28%
147,600 $3.74 Million
Q1 2022

May 16, 2022

BUY
$28.92 - $41.83 $1.9 Million - $2.75 Million
65,700 Added 183.01%
101,600 $3.21 Million
Q4 2021

Feb 14, 2022

SELL
$31.38 - $48.47 $668,394 - $1.03 Million
-21,300 Reduced 37.24%
35,900 $1.45 Million
Q3 2021

Nov 15, 2021

SELL
$26.93 - $37.68 $368,941 - $516,216
-13,700 Reduced 19.32%
57,200 $2 Million
Q2 2021

Aug 11, 2021

BUY
$22.75 - $35.77 $830,375 - $1.31 Million
36,500 Added 106.1%
70,900 $1.95 Million
Q1 2021

May 17, 2021

BUY
$26.16 - $41.39 $551,976 - $873,329
21,100 Added 158.65%
34,400 $966,000
Q4 2020

Feb 16, 2021

SELL
$17.0 - $32.36 $1.06 Million - $2.02 Million
-62,300 Reduced 82.41%
13,300 $345,000
Q3 2020

Nov 16, 2020

BUY
$17.14 - $25.47 $104,554 - $155,367
6,100 Added 8.78%
75,600 $1.3 Million
Q2 2020

Aug 14, 2020

BUY
$13.97 - $36.56 $970,915 - $2.54 Million
69,500 New
69,500 $1.72 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.3B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.